Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 3/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453592 | 0.88 | PARP10 (0.46) | PARP1HSD17B2POLBHPGDRECQL | |
| SCHEMBL3025882 | 0.86 | HSD17B2 (0.61) | PARP1HSD17B2POLBHPGDRECQL | |
| SCHEMBL3454219 | 0.86 | MEP1B (0.48) | PARP1HSD17B2POLBHPGDRECQL | |
| SCHEMBL3455277 | 0.84 | MEN1 (0.49) | PARP1PLAUPLATTAS2R14 | |
| SCHEMBL3034523 | 0.82 | MAOB (0.52) | PARP1HPGDPLAUTAS2R14MAPK8 | |
| SCHEMBL3453561 | 0.78 | PARP10 (0.49) | PARP1PLAU | |
| SCHEMBL3716942 | 0.76 | TAS2R14 (0.55) | HSD17B2PTGESALOX5TAS2R14MEP1B | |
| SCHEMBL3454177 | 0.76 | LCK (0.44) | PARP1PLAU | |
| SCHEMBL3025997 | 0.75 | HPGD (0.58) | PARP1HSD17B2POLBHPGD | |
| SCHEMBL6461963 | 0.75 | SLC2A1 (0.57) | PARP1HSD17B2SLC2A1SLC2A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | BRDT, AADAC, ACIN1 | PARP1 957/4885HSD17B2 892/4885POLB 3269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.